Non-Invasive Liver Iron Quantification by SQUID-Biosusceptometry and Serum Ferritin Iron as New Diagnostic Parameters in Hereditary Hemochromatosis

2002 ◽  
Vol 29 (3) ◽  
pp. 451-458 ◽  
Author(s):  
Peter Nielsen ◽  
Rainer Engelhardt ◽  
Jochen Düllmann ◽  
Roland Fischer
2020 ◽  
Vol 13 (2) ◽  
pp. 712-715
Author(s):  
Mustafa A. Al-Tikrity ◽  
Mohamed A. Yassin

Primary hemochromatosis is an inherited disorder, and the homeostatic iron regulator (HFE) gene C282Y mutation is a common cause of hemochromatosis in Europe. We are reporting a case of a 56-year-old female known to have hemochromatosis with the HFE gene C282Y mutation with a serum ferritin level of 482 μg/L who underwent heart and liver T2* MRI which showed no evidence of iron overload – neither in the heart nor in the liver. This indicates that there is a discrepancy between serum ferritin and liver iron concentration by MRI and the superiority of T2* MRI in diagnosis and follow-up of iron overload in patients with hereditary hemochromatosis.


1996 ◽  
Vol 17 (07) ◽  
pp. 473-479 ◽  
Author(s):  
D. Nachtigall ◽  
P. Nielsen ◽  
R. Fischer ◽  
R. Engelhardt ◽  
E. Gabbe

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3714-3714
Author(s):  
Mauro Marinelli ◽  
Barbara Gianesin ◽  
Antonella Lavagetto ◽  
Martina Lamagna ◽  
Eraldo Oliveri ◽  
...  

Abstract Accurate assessment of body-iron accumulation is essential for managing therapy of iron-chelating diseases characterized by iron overload such as thalassemia, hereditary hemochromatosis, myelodysplasia and other forms of severe anemia. At present, the gold standard to determine liver-iron concentration (LIC) is liver needle biopsy. In this work, we present an alternative non-invasive technique to measure LIC based on a room-temperature susceptometer. SQUID biosusceptometers and MRI are currently the only validated non-invasive methods for LIC measurements. However, SQUIDs are liquid helium-cooled superconducting devices, therefore costly and resource intensive. Furthermore, SQUIDs are only sensitive to a fraction of the liver volume because of their magnetic configuration. MRI requires large magnets with dedicated software and hardware, trained operators, and is accurate only at low iron concentration. The susceptometer presented herein measures iron overload in the whole liver, as the entire human torso fits within its region of sensitivity. Since all of its components operate at room temperature, this susceptometer is more affordable then competing techniques and can reach a wider hospital base. The study was approved by the local Ethics Committee and all subjects gave informed consent. Since February 2005, 40 patients (30 thalassemia major or intermedia, 5 hereditary hemochromatosis, 5 other severe anemia) and 68 healthy volunteers have been measured. The signal picked up by the susceptometer has two sources: an overall magnetic background of the torso and an eventual contribution from liver iron excess. After measuring the magnetic signature of a patient, statistical analysis methods and neural-network simulations (trained using the control data) are employed to estimate the background signal, given the patient anthropometric data. Liver-iron overload is then determined by subtraction of the estimated background from the total measured signal. The refinement of the methodology is in progress and, at present, the error in liver iron is about 1g (SD), corresponding to typical concentrations of 0.5 mg/cm^3. A correlation study between iron overload and blood serum-ferritin concentration in the patient population attained a correlation coefficient R~0.73. Comparison with measurements of LIC via SQUID susceptometry on a subset of 30 patients participating in the present study (carried out by Dr. A. Piga at Ospedale S. Anna, Torino, Italy) yields a correlation coefficient R~0.77. Four patients (3 thalassemia major, 1 hereditary hemochromatosis) under intensive iron depletive therapy have been measured at least twice; our estimate of liver iron reduction is compatible with the clinical data (R~0.76). Comparison with LIC measured via biopsy is in progress. All comparison were blinded. These preliminary results indicate that possible applications of this non-invasive, full-body susceptometer include monitoring the efficacy of the therapy as well as improving the diagnosis and care management of patients with iron overload. Figure Figure


1994 ◽  
Vol 12 (7) ◽  
pp. 999-1007 ◽  
Author(s):  
Rainer Engelhardt ◽  
Joachim H Langkowski ◽  
Roland Fischer ◽  
Peter Nielsen ◽  
Hendrik Kooijman ◽  
...  

Hematology ◽  
2021 ◽  
Vol 26 (1) ◽  
pp. 473-477
Author(s):  
Nattiya Teawtrakul ◽  
Chittima Sirijerachai ◽  
Kanchana Chansung ◽  
Arunee Jetsrisuparb

Biomag 96 ◽  
2000 ◽  
pp. 647-650
Author(s):  
R. Engelhardt ◽  
R. Fischer ◽  
P. Nielsen ◽  
E. E. Gabbe

2017 ◽  
Vol 98 (3) ◽  
pp. 280-288 ◽  
Author(s):  
John B. Porter ◽  
Mohsen Elalfy ◽  
Ali Taher ◽  
Yesim Aydinok ◽  
Szu-Hee Lee ◽  
...  

Blood ◽  
2019 ◽  
Vol 133 (1) ◽  
pp. 18-29 ◽  
Author(s):  
Chia-Yu Wang ◽  
Jodie L. Babitt

Abstract The liver orchestrates systemic iron balance by producing and secreting hepcidin. Known as the iron hormone, hepcidin induces degradation of the iron exporter ferroportin to control iron entry into the bloodstream from dietary sources, iron recycling macrophages, and body stores. Under physiologic conditions, hepcidin production is reduced by iron deficiency and erythropoietic drive to increase the iron supply when needed to support red blood cell production and other essential functions. Conversely, hepcidin production is induced by iron loading and inflammation to prevent the toxicity of iron excess and limit its availability to pathogens. The inability to appropriately regulate hepcidin production in response to these physiologic cues underlies genetic disorders of iron overload and deficiency, including hereditary hemochromatosis and iron-refractory iron deficiency anemia. Moreover, excess hepcidin suppression in the setting of ineffective erythropoiesis contributes to iron-loading anemias such as β-thalassemia, whereas excess hepcidin induction contributes to iron-restricted erythropoiesis and anemia in chronic inflammatory diseases. These diseases have provided key insights into understanding the mechanisms by which the liver senses plasma and tissue iron levels, the iron demand of erythrocyte precursors, and the presence of potential pathogens and, importantly, how these various signals are integrated to appropriately regulate hepcidin production. This review will focus on recent insights into how the liver senses body iron levels and coordinates this with other signals to regulate hepcidin production and systemic iron homeostasis.


Sign in / Sign up

Export Citation Format

Share Document